Viking Therapeutics stock falls 37% on high dropout rate in obesity trial

Viking Therapeutics (VKTX) shares plunged 37% after its Phase 2 VENTURE-Oral Dosing trial for obesity treatment VK2735, while demonstrating strong weight loss efficacy of up to 12.2% over 13 weeks, revealed a concerning 28% treatment discontinuation rate and higher-than-expected gastrointestinal adverse events. Analysts, including Mizuho, highlighted significant competitive disadvantages against Eli Lilly's (LLY) offerings due to the high dropout rate over a shorter trial duration, casting doubt on Viking's near-to-medium term prospects in the oral obesity market, despite JPMorgan acknowledging strong efficacy relative to other oral candidates.

Analysis

Viking Therapeutics (VKTX) experienced a 37% stock price decline following the release of its Phase 2 VENTURE trial data for its oral obesity drug, VK2735. While the drug demonstrated strong efficacy, meeting its primary endpoint with placebo-adjusted weight loss of approximately 7.5% to 11% in its highest-dosing arms over 13 weeks, this positive outcome was severely undermined by a concerning tolerability profile. The key issue driving the negative market reaction was the high treatment discontinuation rate of 28%, significantly above the 18% for placebo. Analysts immediately drew unfavorable comparisons to competitor Eli Lilly (LLY), whose shares gained 1.5% on the news. Mizuho highlighted that LLY's drug achieved a similar dropout rate in the mid-20% range but over a much longer 72-week trial, suggesting a superior long-term tolerability profile for LLY and a significant competitive disadvantage for VKTX. The adverse events underpinning Viking's dropout rate included high instances of vomiting (20-35%) and nausea (~58%) in the treatment arms. Although JPMorgan noted the efficacy was strong relative to other oral candidates in development, the overall investor sentiment indicates that the poor tolerability presents a critical barrier to commercial viability and market acceptance, casting significant doubt on Viking's ability to compete effectively in the oral obesity market in the near-to-medium term.

Key Decisions for Investors

• Investors in Viking Therapeutics should recognize that the high 28% discontinuation rate and adverse event profile present a significant commercialization hurdle, potentially negating the drug's strong efficacy and warranting a re-evaluation of its long-term market potential.
• The trial results reinforce Eli Lilly's competitive moat in the obesity market, as its offering demonstrates a superior tolerability profile over a longer duration, which is a critical factor for patient adherence and long-term prescriptions.
• Future viability for Viking's oral VK2735 is now heavily dependent on demonstrating an improved tolerability profile, making data from its exploratory maintenance dosing arm or any future trials with modified titration schedules the most critical upcoming catalyst to monitor.